$44.41
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating
Hemab Therapeutics' Q2 Net Loss Narrows
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Overview
52-week range
$23
$55
66% of range
Avg surprise (last 0)
—
Avg reaction (last 1)
-0.6%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.80 | — | — | — | — | financials |
| Thu May 21, 2026 | Mar/2026 | $-23.98 | — | — | — | -0.6% | earnings |
| Mon Jun 30, 2025 | Jun 2025 | $-12.91 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-16.18 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-26M | $-24M | — | $-16M | $-17M |
| Net income | $-24M | $-23M | — | $-12M | $-15M |
| EPS (diluted) | $-0.80 | $-23.98 | — | $-12.91 | $-16.18 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $237M | $50M | $88M | — | — |
| Inventory | — | — | — | — | — |
| Total current assets | $464M | $169M | $193M | — | — |
| Total assets | $468M | $175M | $195M | — | — |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $14M | $14M | $11M | — | — |
| Total equity | $454M | $-199M | $-177M | $-141M | $-129M |
Implied volatility — last 90 days
No IV snapshots yet for COAG.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.